Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:158:4-16.
doi: 10.1016/j.addr.2020.06.018. Epub 2020 Jun 24.

Advanced drug delivery 2020 and beyond: Perspectives on the future

Affiliations
Review

Advanced drug delivery 2020 and beyond: Perspectives on the future

You Han Bae et al. Adv Drug Deliv Rev. 2020.

Abstract

Drug delivery systems are developed to maximize drug efficacy and minimize side effects. As drug delivery technologies improve, the drug becomes safer and more comfortable for patients to use. During the last seven decades, extraordinary progress has been made in drug delivery technologies, such as systems for long-term delivery for months and years, localized delivery, and targeted delivery. The advances, however, will face a next phase considering the future technologies we need to overcome many physicochemical barriers for new formulation development and biological unknowns for treating various diseases. For immediate and long-term progress into the future, the drug delivery field should use time and resources for more translatable research ideas. The drug delivery discipline has to continue working on basic, applied, translational, and clinical research in a concerted manner to produce drug delivery systems that work for patients. It is a time to focus our attention on things that matter. It is also a time to develop realistic research goals and outcomes, diversify drug delivery technologies, and take the collective responsibility for our actions.

Keywords: Diverse technologies; Drug delivery issues; Drug prices; Nanomedicine; Optimal target diseases; Preclinical-clinical correlation.

PubMed Disclaimer

References

    1. Lawrence J, Making drugs work better: four new drug delivery methods, Acute pain, 10 (2019) 00.
    1. A. Update, AAPS Update, Pharmaceutical Research 24 (2007) 201–202.
    1. Veronese F, Bevilacqua R, Schiavon O, Rodighiero G, Drug-protein interaction: plasma protein binding of furocoumarins, Il Farmaco; edizione scientifica, 34 (1979) 716–725. - PubMed
    1. Scherphof G, Roerdink F, Waite M, Parks J, Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins, Biochimica et biophysica acta, 542 (1978) 296–307. - PubMed
    1. Larson N, Ghandehari H, Polymeric conjugates for drug delivery, Chemistry of Materials, 24 (2012) 840–853. - PMC - PubMed

Publication types

MeSH terms